News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,344 Results
Type
Article (42011)
Company Profile (331)
Press Release (667002)
Section
Business (210212)
Career Advice (2083)
Deals (36598)
Drug Delivery (100)
Drug Development (82892)
Employer Resources (171)
FDA (16507)
Job Trends (15366)
News (355587)
Policy (33840)
Tag
Academia (2574)
Alliances (51258)
Alzheimer's disease (1306)
Approvals (16469)
Artificial intelligence (173)
Bankruptcy (364)
Best Places to Work (11733)
Biotechnology (213)
Breast cancer (207)
Cancer (1544)
Cardiovascular disease (128)
Career advice (1742)
CAR-T (108)
Cell therapy (314)
Clinical research (66456)
Collaboration (579)
Compensation (311)
COVID-19 (2620)
C-suite (135)
Data (1476)
Diabetes (189)
Diagnostics (6279)
Earnings (86705)
Employer resources (149)
Events (113209)
Executive appointments (484)
FDA (17288)
Funding (516)
Gene therapy (226)
GLP-1 (654)
Government (4459)
Healthcare (18920)
Infectious disease (2717)
Inflammatory bowel disease (118)
Interviews (320)
IPO (16665)
Job creations (4052)
Job search strategy (1488)
Layoffs (445)
Legal (8335)
Lung cancer (227)
Manufacturing (223)
Medical device (13318)
Medtech (13323)
Mergers & acquisitions (20181)
Metabolic disorders (510)
Neuroscience (1677)
NextGen: Class of 2025 (6631)
Non-profit (4519)
Northern California (1868)
Obesity (292)
Opinion (213)
Patents (137)
People (58589)
Phase I (20592)
Phase II (29239)
Phase III (21923)
Pipeline (615)
Postmarket research (2652)
Preclinical (8740)
Radiopharmaceuticals (244)
Rare diseases (296)
Real estate (6243)
Regulatory (22635)
Research institute (2362)
Resumes & cover letters (358)
Southern California (1614)
Startups (3715)
United States (16733)
Vaccines (597)
Weight loss (210)
Date
Today (33)
Last 7 days (392)
Last 30 days (1882)
Last 365 days (35379)
2025 (1626)
2024 (35808)
2023 (40635)
2022 (51798)
2021 (56329)
2020 (54794)
2019 (47400)
2018 (35772)
2017 (33142)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (210)
Asia (40267)
Australia (6439)
California (4244)
Canada (1556)
China (370)
Colorado (192)
Connecticut (206)
Europe (85712)
Florida (598)
Georgia (146)
Illinois (422)
Indiana (247)
Maryland (688)
Massachusetts (3316)
Michigan (184)
Minnesota (315)
New Jersey (1194)
New York (1203)
North Carolina (798)
Northern California (1868)
Ohio (152)
Pennsylvania (1000)
South America (1159)
Southern California (1614)
Texas (619)
Utah (120)
Washington State (434)
709,344 Results for "ionis pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Ionis’ Tryngolza Becomes First FDA-Approved Therapy for Familial Chylomicronemia Syndrome
Despite securing the industry’s first approval for familial chylomicronemia syndrome, BMO Capital Markets believes that Tryngolza’s regulatory triumph will not be a significant positive for Ionis. Instead, the firm is focusing on olezarsen’s readout in severe hypertriglyceridemia, a much larger market.
December 20, 2024
·
2 min read
·
Tristan Manalac
Biotech Beach
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines & RNA Summit on Thursday, June 20, 2024.
June 17, 2024
·
1 min read
Business
Ionis reports first quarter 2024 financial results
Ionis Pharmaceuticals, Inc., reported financial results for the first quarter ended March 31, 2024.
May 7, 2024
·
15 min read
Biotech Beach
Ionis Publishes 2023 Corporate Responsibility Report
Ionis Pharmaceuticals, Inc. today published its 2023 Corporate Responsibility Report: Action for a Healthier Future.
April 25, 2024
·
7 min read
Press Releases
Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
·
1 min read
Biotech Beach
Ionis to host 2024 virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 6, 2024.
May 15, 2024
·
2 min read
Biotech Beach
Ionis to present at upcoming investor conferences - April 01, 2024
Ionis Pharmaceuticals, Inc. announced that management will participate in fireside chats at the following investor conferences.
April 1, 2024
·
1 min read
Biotech Beach
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Ionis Pharmaceuticals, Inc. announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. under which Otsuka obtains exclusive rights across the Asia-Pacific region for donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema.
June 18, 2024
·
5 min read
Press Releases
Ionis to present at upcoming investor conferences
November 8, 2024
·
1 min read
Press Releases
PANTHERx® Rare Selected by Ionis as Specialty Pharmacy for TRYNGOLZA™ (olezarsen)
December 23, 2024
·
3 min read
1 of 70,935
Next
